Department of Cancer Center, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.
J Cancer Res Clin Oncol. 2020 Sep;146(9):2329-2338. doi: 10.1007/s00432-020-03296-6. Epub 2020 Jun 28.
With the development of antitumor therapies, different treatment methods including monotherapy and combined therapy have achieved clinical efficacy in advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients. Exon 19 deletion (ex19del) and exon 21 L858R mutation are common sensitive subtypes of EGFR mutation. However, potential distinct mechanisms are found from several dimensions including molecular structures, biological behaviors, concomitant mutations, resistance mechanisms and tumor mutation burdens. More evidence indicates the prognostic difference of EGFR subgroups. This review focused on the progress of potential distinct mechanisms and outcomes in clinical trials of advanced NSCLC patients with ex19del or exon 21 L858R mutation.
随着抗肿瘤疗法的发展，不同的治疗方法，包括单药治疗和联合治疗，在晚期表皮生长因子受体（EGFR）突变非小细胞肺癌（NSCLC）患者中已取得临床疗效。外显子 19 缺失（ex19del）和外显子 21 L858R 突变是 EGFR 突变的常见敏感亚型。然而，从分子结构、生物学行为、伴随突变、耐药机制和肿瘤突变负担等多个维度发现了潜在的不同机制。更多证据表明 EGFR 亚组的预后存在差异。本综述重点介绍了晚期 NSCLC 患者中 ex19del 或 exon 21 L858R 突变的临床试验中潜在不同机制和结果的进展。
